Zobrazeno 1 - 10
of 88
pro vyhledávání: '"antimycobacterial therapy"'
Autor:
Angelo Roberto Raccagni, Giovanni Mori, Valeria Poletti de Chaurand, Raffaele Dell’Acqua, Daniela Maria Cirillo, Chiara Oltolini, Benedetta Mazzi, Francesco Scomazzoni, Antonella Castagna, Monica Guffanti
Publikováno v:
Annals of Clinical Microbiology and Antimicrobials, Vol 23, Iss 1, Pp 1-9 (2024)
Abstract Background Disseminated non-tuberculous mycobacteria (dNTM) infections are mostly reported among individuals with an underlying congenital or acquired immunodeficiency or receiving immunosuppressive treatment, but are rarely documented in ot
Externí odkaz:
https://doaj.org/article/7797da80cd7941629469d5a1df1d584b
Publikováno v:
Zaporožskij Medicinskij Žurnal, Vol 25, Iss 2, Pp 178-183 (2023)
Aim. To analyze the effectiveness and safety of a modified short-term regimen (mSTR) of antimycobacterial therapy (AMBT) for rifampicin-resistant tuberculosis (RR-TB) in a 71-year-old patient with type 2 diabetes mellitus (T2DM) on the clinical case
Externí odkaz:
https://doaj.org/article/e752a2828da743eabeb31b01dc2e35bb
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Ясінський, Р. M.
Publikováno v:
Запорізький медичний журнал; Том 25 № 2 (2023): Запорізький медичний журнал; 178-183
Запорожский медицинский журнал; Том 25 № 2 (2023): Запорізький медичний журнал; 178-183
Zaporozhye Medical Journal; Vol. 25 No. 2 (2023): Zaporozhye medical journal; 178-183
Запорожский медицинский журнал; Том 25 № 2 (2023): Запорізький медичний журнал; 178-183
Zaporozhye Medical Journal; Vol. 25 No. 2 (2023): Zaporozhye medical journal; 178-183
Aim. To analyze the effectiveness and safety of a modified short-term regimen (mSTR) of antimycobacterial therapy (AMBT) for rifampicin-resistant tuberculosis (RR-TB) in a 71-year-old patient with type 2 diabetes mellitus (T2DM) on the clinical case
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=scientific_p::46a6ac8741990468f4d0ef91b650bbad
http://zmj.zsmu.edu.ua/article/view/269508
http://zmj.zsmu.edu.ua/article/view/269508
Publikováno v:
Frontiers in Pharmacology, Vol 9 (2018)
Tuberculosis is one of the leading cause of death worldwide, particularly due to evolution of drug resistant strains. Antitubercular peptides may provide an alternate approach to combat antibiotic tolerance. Sequence analysis reveals that certain res
Externí odkaz:
https://doaj.org/article/8550fd6502474fdca66a8941027e84d1
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Publikováno v:
Буковинський медичний вісник; Том 15 № 3(59) (2011); 255-259
Буковинский медицинский вестник; Том 15 № 3(59) (2011); 255-259
Bukovinian Medical Herald; Vol. 15 No. 3(59) (2011); 255-259
Буковинский медицинский вестник; Том 15 № 3(59) (2011); 255-259
Bukovinian Medical Herald; Vol. 15 No. 3(59) (2011); 255-259
An analysis of the epidemiological indices in Bukovina from 2008 through 2009 has demonstrated further spread of strains of the mycobacteria of tuberculosis (MBT) with acquired multiple resistance to 1-st lines drugs with an evident trend towards an
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=scientific_p::c51caf422e0b81f4fc5ee2217ffe3e25
http://e-bmv.bsmu.edu.ua/article/view/233207
http://e-bmv.bsmu.edu.ua/article/view/233207
Publikováno v:
International Journal of Mycobacteriology, Vol 5, Iss 5, Pp 110-111 (2016)
Objective/Background: The aim of this work was to study the efficacy and safety of quercetin and polyvinylpyrrolidone (QP) in the treatment of patients with newly diagnosed destructive pulmonary tuberculosis (TB) in comparison with standard antimycob
Externí odkaz:
https://doaj.org/article/390dbd9cb5d54e379966867d2f41fe20
Phase II Investigation of the Efficacy of Antimycobacterial Therapy in Chronic Pulmonary Sarcoidosis
Autor:
Elliott D. Crouser, Amy Kerrigan, Marc A. Judson, Daniel A. Culver, Tan Ding, Abena Green, Ahmed Sesay, K. Abel, Gregory D. Ayers, Gordon R. Bernard, Wonder P. Drake, Robert P. Baughman, W. Ennis James
Publikováno v:
Chest
Background A Phase I, single-center investigation found that 8 weeks of antimycobacterial therapy improved sarcoidosis FVC. Safety and efficacy assessments have not been performed in a multicenter cohort. Research Question The objective of this study
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::01c082ed44ab03040e7cc9a1aabfd19a
https://pubmed.ncbi.nlm.nih.gov/33387486
https://pubmed.ncbi.nlm.nih.gov/33387486